share_log

BioHarvest Sciences Announces a Private Placement of up to USD $5 Million and Conversion of Debt Notes

BioHarvest Sciences Announces a Private Placement of up to USD $5 Million and Conversion of Debt Notes

BioHarvest Sciences宣佈最多500萬美元的定向增發和債務轉換。
newsfile ·  06/21 08:30

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 21, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) ("BioHarvest" or the "Company"), announced today that its board of directors have approved a private placement of up to 697,350 units at a price of USD $7.17 per unit (approx. CAD $9.82) for gross proceeds of up to USD $5,000,000 (approx. CAD $6,847,000).

溫哥華,不列顛哥倫比亞省和以色列萊霍武特-新聞稿公司-2024年6月21日-BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) (BioHarvest或本公司)今日宣佈,其董事會已批准以每股7.17美元(約爲9.82加元)的價格,最多發行697,350個單位的定向增發,募集美金500萬美元(約爲6,847,000加元)的總收益。

Each Unit includes one common share, one-quarter (1/4) of a USD $7.68 Warrant (approx. CAD $10.50), and one-quarter (1/4) of an USD $11.52 Warrant (approx. $15.77 CAD). A full USD $7.68 Warrant allows the holder to buy one common share at USD $7.68 within six months from the issue date. Similarly, a full USD $11.52 Warrant allows the holder to buy one common share at USD $11.52 within eighteen months from the issue date. The Company will pay (to registered investment dealers or finders, where permitted by law) cash commissions or finders fees of up to 5% of the cash proceeds of the offering.

每個單位包括一股普通股,1/4個7.68美元贖回證(約爲10.50加元),以及1/4個11.52美元贖回證(約爲15.77加元)。完整的7.68美元贖回證允許持有人在發行日期後六個月內以7.68美元的價格購買一股普通股。同樣,完整的11.52美元贖回證將允許持有人在發行日期後十八個月內以11.52美元的價格購買一股普通股。公司將支付(給註冊的投資交易商或發現人,如果法律允許)現金佣金或募集款項的5%的發現人費用。

Funds raised through this private placement will be allocated to advancing the Company's Contract Development and Manufacturing Organization (CDMO) business unit, expanding the Company's manufacturing capabilities within the newly acquired 80,000 square foot campus, and for general corporate purposes.

通過此次定向增發募集的資金將用於推進公司的合同開發和製造組織(CDMO)業務部,擴展公司在新收購的80,000平方英尺校園內的製造能力,以及用於一般公司用途。

In addition, the Company announces an early conversion of convertible debt notes, associated with the convertible debt financing rounds completed on July, October and December 2023.

此外,公司宣佈早期轉換可轉債注資,這些注資與2023年7,10,12月完成的可轉債融資輪相關。

BioHarvest reports that a total of CAD $1,331,254.50 (approx. USD $972,348) of principal loans plus accrued interest has been converted into 161,620 common shares. As part of the term of October and December 2023 convertible loans, the Company has issued 114,236 "Early Exercise" warrants at USD 7.70 for early conversion. 107,617 "Early Exercise" warrants will expire on October 30, 2025, and 6,619 will expire on December 22, 2025.

BioHarvest報告,總額爲CAD 1,331,254.50加元(約爲972,348美元)的本金貸款及應計利息已轉換爲161,620股普通股。作爲2023年10月和12月可轉債貸款條款的一部分,公司已發行了114,236個“早期行權”認股權證,以7.70美元進行早期轉換。107,617個“早期行權”認股權證將於2025年10月30日到期,6,619個將於2025年12月22日到期。

As a result of this conversion, over 90% of the Company's convertible notes have now been exercised.

因此,公司的可轉債票據已有超過90%進行了行權。

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc.簡介

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit .

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) (FSE: 8MV) 是植物合成領域的領導者,利用其獲得專利的技術平台生產植物基分子,無需培養基礎植物。BioHarvest正在利用其植物合成技術開發下一代基於科學研究的和臨床證明的治療方案,包括兩個主要業務垂直領域;作爲一家代表尋求複雜分子的客戶的合同開發和生產組織公司(CDMO),以及作爲專有保健品健康和健康產品創造者的公司,包括膳食補充劑。有關更多信息,請訪問

Forward-Looking Statements

前瞻性聲明

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

本新聞稿中的信息可能包含基於管理層的當前估計、信念、意圖和期望而基於的前瞻性聲明,且可能受到一系列風險和不確定性的影響,這可能導致實際結果與前瞻性聲明中描述的結果有所不同。所有前瞻性聲明本質上都是不確定的,實際結果可能會受到我們控制之外的一些實質性因素的影響。讀者不應過度依賴前瞻性聲明。BHSC無意通過常規管理討論和分析披露之外的其他方式更新前瞻性聲明披露。

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

加拿大證券交易所及其監管服務提供商不承擔本發佈內容的充分性或準確性的責任。

This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.

此新聞稿內容已由Dave Ryan, VP Investor Relations審核並批准。

BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
+1 (604) 622-1186
info@bioharvest.com

BioHarvest的公司聯繫方式:
Dave Ryan,投資者關係和董事副總裁
+1 (604) 622-1186
info@bioharvest.com

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us

投資者關係聯繫人:
Lucas A. Zimmerman
董事總經理
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論